Patricia Inácio, PhD, science writer —

Treatment with mepolizumab, an antibody designed to lower the levels of eosinophils — immune cells linked with worse chronic obstructive pulmonary disease (COPD) — was found to reduce the annual rate of exacerbations and improve health-related quality of life in people with eosinophil-associated COPD. The findings, from a meta-analysis…

Approximately 40% of chronic obstructive pulmonary disease (COPD) patients in the U.S. — and notably, most of those living in small towns or rural areas — have limited access to pulmonary rehabilitation (PR) maintenance programs, according to a recent study. Indeed, roughly 17% of people with COPD from this…

Note: This story was updated May 21, 2021, as an earlier version of this article misidentified Renu Jain, PhD, scientific director of medical affairs at GlaxoSmithKline.  People with chronic obstructive pulmonary disease (COPD) who do not experience exacerbations, or flare-ups, within the previous 12 months are still at risk…

The Chronic Obstructive Pulmonary Disease Foundation and DevPro Biopharma have established a partnership to develop new therapies for people with chronic obstructive pulmonary disease (COPD) and other lung disorders. The collaborators will work to identify potential therapies and speed their development and possible regulatory approval. The aim is to enable new treatments…

Patients with chronic obstructive pulmonary disease (COPD) are more likely to develop ventricular arrhythmia, a heart rhythm disorder affecting the heart’s lower chambers or ventricles, than people without the disease, according to a Taiwanese nationwide study. Later analysis of that study also found that people with both COPD and…

A new collaboration is seeking to bring quantitative imaging analysis to diagnosis and care of patients with chronic lung diseases, including chronic obstructive pulmonary disease (COPD) and emphysema. The agreement is between Spesana, a healthcare platform focused on molecular diagnostics and in building an accessible database for physicians,…

People in China with chronic obstructive pulmonary disease (COPD) are overusing inhaled corticosteroids and underusing non-pharmacological therapies such as home oxygen therapy, a study suggests. The real-world data show that treatment of COPD patients fails to follow the 2017 revised Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines.

The European Commission has approved AstraZeneca‘s triple combination therapy Trixeo Aerosphere as a maintenance treatment for chronic obstructive pulmonary disease (COPD). The approval, which follows a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), covers the therapy’s use in adults with moderate-to-severe COPD…

Nuvaira’s targeted lung denervation (TLD) therapy lowers the risk of hospitalization due to exacerbations in people with chronic obstructive pulmonary disease (COPD), Phase 2 trial data show, according to a company press release. A new clinical study, called AIRFLOW-3 (NCT03639051), is currently recruiting COPD patients at multiple…

Use of electronic cigarettes (e-cigarettes) is associated with an increased risk of respiratory diseases, including chronic obstructive pulmonary disease (COPD), among young adults, irrespective of other tobacco product use, a large U.S.-based study shows. Compared to healthy people, those currently using e-cigarettes, commonly called vaping, had a 43% increased…